AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, …
$142.50-1.07%
报价 2026-11-06
市值
$9.03B
EV
$9.09B
PE (TTM)
22.0x
预期 PE (FY2026)
25.7x
52 周区间距高点 -3.0%
$111.94$146.86
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 5.38 → 6.20（1.2x） | 23.0 |
| FY+32028-12 | 1.1x | 5.38 → 6.87（1.3x） | 20.8 |
毛利率 28% · TTM 收入 $3991M · 基数 EPS 5.38（调整后）
电话会信号
辅助标签Q3 20262026-10-30
扩产
指引 无
信心 4
分析师 3
“We expect to finish 2026 strong, driven by Pharma, with margin improvement in Q4.”
原文引用（1）
- 扩产：we increased capacity in Europe
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ATRAptarGroup, Inc. | $9.03B | -1.1% | +8.7% | 27.8% | 22.0x | 11.1x | 25.3x | |
| HALOHalozyme Therapeutics, Inc. | $11.76B | -15.7% | +27.0% | 78.2% | 29.3x | 20.9x | 15.2x | |
| RGENRepligen Corporation | $11.09B | +3.0% | +15.8% | 53.1% | 233.1x | 56.2x | 87.9x | |
| MOHMolina Healthcare, Inc. | $10.91B | -3.5% | -0.6% | 8.2% | – | 31.2x | 45.8x | |
| AVTRAvantor, Inc. | $10.48B | +2.2% | +2.2% | 31.5% | 30.9x | 15.1x | 23.9x | |
| HSICHenry Schein, Inc. | $9.59B | +0.9% | +5.8% | 31.8% | 24.9x | 12.7x | 17.8x | |
| GMEDGlobus Medical, Inc. | $9.54B | -12.8% | +9.9% | 67.4% | 21.9x | 13.9x | 16.5x | |
| GRFSGrifols, S.A. | $7.13B | -0.4% | – | 38.4% | 15.2x | 10.0x | – | |
| TFXTeleflex Incorporated | $6.39B | -0.8% | -30.7% | 53.3% | – | 63.6x | 26.1x | |
| 同行中位数 | – | – | +5.8% | 45.7% | 27.1x | 18.0x | 23.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.03B | $982.9M | $962.7M | $961.1M | $966M | $887.3M | $848.1M | $909.3M |
| Gross Margin | 27.8% | 28.1% | 27.2% | 29.9% | 30.8% | 30.5% | 38.8% | 38.6% |
| Operating Margin | 12.5% | 11.1% | 11.5% | 14.5% | 15.1% | 13% | 14.2% | 15.2% |
| Net Income | $87.6M | $72.7M | $74.3M | $127.9M | $111.7M | $78.8M | $100.9M | $100M |
| Diluted EPS | 1.36 | 1.12 | 1.13 | 1.92 | 1.67 | 1.17 | 1.49 | 1.48 |
| Operating Cash Flow | $103.5M | $118.7M | $183.7M | $177.6M | $126M | $82.7M | $178.2M | $229.3M |